| 2025-11-13 |
详情>>
内部人交易：
SROKA DIANA股份减少1343.00股
|
| 2025-11-10 |
详情>>
股本变动：
变动后总股本42009.59万股
|
| 2025-11-10 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-0.13美元,归母净利润-5406.3万美元,同比去年增长41.55%
|
| 2025-11-06 |
财报披露：
美东时间 2025-11-06 盘后发布财报
|
| 2025-08-11 |
详情>>
业绩披露：
2025年中报每股收益0.14美元,归母净利润5491.10万美元,同比去年增长177.62%
|
| 2025-05-12 |
详情>>
业绩披露：
2025年一季报每股收益0.33美元,归母净利润1.29亿美元,同比去年增长487.46%
|
| 2025-04-28 |
股东大会：
将于2025-05-23召开股东大会
会议内容 ▼▲
- 1.To elect Dr. Keyvan Mohajer, James Hom, Larry Marcus, Diana Sroka and Dr. Eric Ball as directors (the “Director Nominees”) to serve on the Company’s Board of Directors (the “Board”) for a one-year term that expires at the 2026 Annual Meeting of Stockholders, or until their successors are elected and qualified;
2.To ratify the appointment by the Board of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025;
3.To consider and vote upon an amendment to Section 4.1 of Article IV of the Company’s Second Amended and Restated Certificate of Incorporation to increase the number of authorized shares of Class A Common Stock, $0.0001 par value per share, from 455,000,000 to 755,000,000 (the “Authorized Share Proposal”);
4.To consider and vote upon an amendment to Section 12.1 of Article XII of the Company’s Second Amended and Restated Certificate of Incorporation regarding the waiver of corporate opportunities (the “Opportunity Waiver Limitation Proposal”);
5.To consider and vote upon an amendment to Article VIII of the Company’s Second Amended and Restated Certificate of Incorporation to provide for officer exculpation (the “Officer Exculpation Proposal”);
6.To consider and vote upon amendments to Article IV and Article X of the Company’s Second Amended and Restated Certificate of Incorporation to adjust the voting requirements for certain future amendments to the charter in accordance with recent amendments to Section 242(d) of the Delaware General Corporation Law (the “242(d) Proposal”);
7.To consider and vote upon an amendment to Section 5.2 of Article V of the Company’s Second Amended and Restated Certificate of Incorporation to remove subsection 5.2.2 relating to the ratification of contracts and acts by stockholders (the “Stockholder Ratification Proposal”);
8.To transact such other business as may properly come before the Annual Meeting or any adjournment thereof.
|
| 2025-03-11 |
详情>>
业绩披露：
2022年年报每股收益-0.74美元,归母净利润-1.17亿美元,同比去年增长-46.73%
|
| 2025-03-11 |
详情>>
业绩披露：
2024年年报每股收益-1.04美元,归母净利润-3.51亿美元,同比去年增长-282.83%
|
| 2024-11-12 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-0.28美元,归母净利润-9249.8万美元,同比去年增长-26.47%
|
| 2024-08-09 |
详情>>
业绩披露：
2023年中报每股收益-0.25美元,归母净利润-5229.6万美元,同比去年增长6.23%
|
| 2024-08-09 |
详情>>
业绩披露：
2024年中报每股收益-0.23美元,归母净利润-7074.7万美元,同比去年增长-35.28%
|
| 2024-05-10 |
详情>>
业绩披露：
2024年一季报每股收益-0.12美元,归母净利润-3335.2万美元,同比去年增长-18.64%
|
| 2024-04-29 |
股东大会：
将于2024-06-12召开股东大会
会议内容 ▼▲
- 1.To elect Dr. Keyvan Mohajer, James Hom, Larry Marcus, Diana Sroka and Dr. Eric Ball as directors (the “Director Nominees”) to serve on the Board for a one-year term that expires at the 2025 Annual Meeting of Stockholders, or until their successors are elected and qualified;
2.To ratify the appointment by the Board of PricewaterhouseCoopers LLP (the “Auditor”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024;
3.To approve, on a non-binding, advisory basis, the compensation of our named executive officers;
4.To select, on a non-binding, advisory basis, the frequency of conducting future stockholder advisory votes on named executive officer compensation (which will be either every year, every two years or every three years);
5.To transact such other business as may properly come before the Annual Meeting or any adjournment thereof.
|
| 2024-03-01 |
详情>>
业绩披露：
2023年年报每股收益-0.4美元,归母净利润-9171.1万美元,同比去年增长21.42%
|
| 2023-11-15 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-0.33美元,归母净利润-7314万美元,同比去年增长14.79%
|
| 2023-05-30 |
股东大会：
将于2023-06-29召开股东大会
会议内容 ▼▲
- 1.To elect Dr. Keyvan Mohajer, James Hom, Larry Marcus, Diana Sroka and Dr. Eric Ball as directors (the “Director Nominees”) to serve on the Company’s Board of Directors (the “Board”) for a one-year term that expires at the 2024 Annual Meeting of Stockholders, or until their successors are elected and qualified;
2.To ratify the appointment by the Board of Armanino LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023;
3.To transact such other business as may properly come before the Annual Meeting or any adjournment thereof.
|
| 2022-05-12 |
复牌提示：
2022-05-12 11:19:03 停牌，复牌日期 2022-05-12 11:29:03
|